Celgene International Sàrl 보도자료 - 뉴스와이어

기업 뉴스룸

Celgene International Sàrl

제약

BOUDRY, Switzerland

Celgene International Sàrl 보도자료

15개

RSS 이메일

2017년 2월 3일 10:10

Celgene Receives Positive CHMP Opinion to Expand REVLIMID® (Lenalidomide) Indication as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma (MM) after Autologous Stem Cell Transplantation

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of

건강 제약 개발

2017년 2월 3일 10:10

유럽 약물사용자문위원회(CHMP), 자가 조혈모세포이식술 후 다발성 골수종으로 새로 진단된 환자의 유지치료를 위한 단독요법으로 세엘진의 ‘레블리미드’(레날리도마이드)의 적응증을 확대하도록 긍정적 의견 채택

유럽의약청(EMA) 산하 약물사용자문위원회(CHMP)가 ‘레블리미드’(REVLIMID®)를 자가 조혈모세포이식(ASCT)술을 받은 후 다발성 골수종(MM)으로 새로 진단된 성인환자의 유지 치료를 위한 단독요법으로 사용할 수 있다는 긍정적인 의견을 채택했다고 세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)의 완전 소유 자회사인 세엘진 인터내셔널(Celgene International

건강 제약 개발

2016년 9월 19일 10:25

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposure on treatment) of the RADIANCE phase 2 trial of o

건강 제약 개발

2015년 12월 21일 15:45

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan’s Ministry

건강 제약 개발

2015년 10월 13일 09:50

One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from its ongoing phase III LIBERATE™ trial evaluating Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodi

건강 제약 개발

2015년 10월 12일 09:25

Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the latest research on Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), will be presented at

건강 제약 개발

2015년 9월 25일 16:40

Celgene’s VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ex

건강 제약 개발

2015년 3월 3일 17:00

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combina

건강 제약 개발

2015년 2월 23일 11:55

REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult patients with previously untreated multipl

건강 제약 개발

2015년 1월 28일 10:45

Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE®

건강 제약 개발

2015년 1월 19일 11:00

Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis

Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA® (apremilast), the company’s oral selective inhibitor of pho

건강 제약 개발

2014년 12월 22일 13:35

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for continuou

건강 제약 개발

2014년 10월 21일 13:05

Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will

건강 제약 개발

2014년 10월 13일 11:40

New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the ESTEEM phase III clinical trial program were releas

건강 제약 개발

2014년 10월 13일 11:35

Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that patient-reported health outcomes data for OTEZLA® (apremilast) were presented at the 23rd European Academy of Dermatology and Venereology

건강 제약 개발